Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02089087 · ClinicalTrials.gov registry record · Phase 1

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Dose CFZ533 in Rheumatoid Arthritis Patients

A Phase 1 study of Rheumatoid Arthritis, sponsored by Novartis Pharmaceuticals.

Completed
Registry status
Phase 1
Development phase
75
Enrollment target
6
Study locations

NCT02089087 is a Phase 1 study of Rheumatoid Arthritis that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 75 participants, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (98% lower). The trial reports 6 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02089087, a Phase 1 study of Rheumatoid Arthritis, has completed, sponsored by Novartis Pharmaceuticals.

COMPLETED
Registry status
Phase 1
Development phase
75 participants
Enrollment target
6
Study locations

Study Summary

This is a first-in-human study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single intravenous and subcutaneous doses of CFZ533 in healthy subjects and intravenous doses in rheumatoid arthritis patients.

Conditions Studied

Rheumatoid Arthritis

Interventions

  • DRUG Placebo
  • BIOLOGICAL CFZ533

Study Locations (6)

Florida

  • Novartis Investigative Site - Miami
  • Novartis Investigative Site - South Miami

Alabama

  • Novartis Investigative Site - Anniston

Nebraska

  • Novartis Investigative Site - Lincoln

Pennsylvania

  • Novartis Investigative Site - Duncansville

Other

  • Novartis Investigative Site - Taipei

Trial Details

FieldValue
Enrollment Target 75 participants
Start Date 2013-01-07
Est. Completion 2017-02-03
Phase Phase 1

Sponsor

Novartis Pharmaceuticals

1,375 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT02089087

The ClinicalTrials.gov registry entry for NCT02089087 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 4,690-participant average among 197 other Rheumatoid Arthritis trials with a reported enrollment target (98% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Rheumatoid Arthritis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT02089087 reports 6 study locations spanning 5 distinct geographic areas - top geographies include Florida, Alabama, Nebraska.

Frequently Asked Questions

What is clinical trial NCT02089087 about?

NCT02089087 is a clinical study titled "Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Dose CFZ533 in Rheumatoid Arthritis Patients". This is a first-in-human study to investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single intravenous and subcutaneous doses of CFZ533 in healthy subjects and intravenous doses in rheumatoid arthritis patients.

What is the current status of trial NCT02089087?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 75 participants. The study started on 2013-01-07. Estimated completion is 2017-02-03.

What conditions does trial NCT02089087 study?

This clinical trial studies the following conditions: Rheumatoid Arthritis.

What interventions are being tested in trial NCT02089087?

The interventions under investigation include: Placebo (DRUG), CFZ533 (BIOLOGICAL).

Who is sponsoring clinical trial NCT02089087?

This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02089087 being conducted?

This trial has 6 study locations across Alabama, Florida, Nebraska, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Rheumatoid Arthritis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Rheumatoid Arthritis

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.